Valenzabio, Inc., A Biopharmaceutical Company Developing Monoclonal Antibody (Mab) Therapeutics For Autoimmune And Inflammatory Indications, And Novelty Nobility Inc, A Biotechnology Company Specializing In The Design, Discovery, Optimization, And Early Stage Development Of Next Generation Antibodies, Today Announced An Exclusive Worldwide License Agreement For The Development And Commercialization Of Vb517, A Potentially Best-In-Class Anti-C-Kit Mab For Mast Cell-Driven Autoimmune Diseases. C-Kit Is A Receptor Tyrosine Kinase Critical To The Survival And Activation Of Mast Cells. Blocking C-Kit Has Been Shown To Reduce Mast Cell Degranulation And Induce Mast Cell Depletion In Clinical Studies. Vb517 Is A Fully Human Mab With Low-Picomolar Affinity For C-Kit And Has Demonstrated Potent Suppression Of Human Mast Cell Activation In Preclinical Models. Valenzabio Plans To Initiate Clinical Studies Of Vb517 In 2023.
